Mutual funds are subject to market risk. Read all scheme documents carefully.
The fund is rated 0.5 stars. Investment selection within each industry provided some support. Investment selection within each asset type and balance between returns and downside risk were the main limitations and did not provide enough support for a higher rating. Higher annual fee of 2.12% and above-average fund size of Rs 3,501.37 crore were minor drawbacks.
This fund has a bad track record with Asset Selection/Timing, a ok track record with Stock Selection/Timing, a bad risk-reward ratio. It is important to note, however, that this fund has a 3501.368 AUM and a 2.12 expense ratio. Considering all these factors, we have rated this fund as 0.5 star.
Our score weighs long-term performance, risk and consistency — not just past returns.
As of 5 Nov 2026
As of 31 Oct 2026
To generate long-term capital appreciation Investment predominantly in equity & equity related instruments of Pharma and healthcare companies.
The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
Exit load of 1%, if redeemed within 30 days.
As of 30 Sep 2026
| Holding | % of fund | Value | Shares |
|---|---|---|---|
| Divi's Laboratories Ltd. | 9.39% | ₹328.63 Cr | 3,53,687 |
| Sun Pharmaceutical Industries Ltd. | 8.28% | ₹289.76 Cr | 15,95,093 |
| Others | 4.67% | ₹163.43 Cr | — |
| Alkem Laboratories Ltd. | 4.64% | ₹162.58 Cr | 3,14,859 |
| Cipla Ltd. | 4.15% | ₹145.37 Cr | 10,80,050 |
| Apollo Hospitals Enterprise Ltd. | 3.69% | ₹129.18 Cr | 1,58,200 |
| Torrent Pharmaceuticals Ltd. | 3.65% | ₹127.91 Cr | 2,66,486 |
| Max Healthcare Institute Ltd. | 3.61% | ₹126.42 Cr | 13,59,696 |
| Aster DM Quality Care Ltd. | 3.56% | ₹124.51 Cr | 17,86,027 |
| Lupin Ltd. | 3.55% | ₹124.15 Cr | 6,11,505 |
